123 related articles for article (PubMed ID: 16026845)
1. Pathophysiological basis of drug-induced dyskinesias in Parkinson's disease.
Deogaonkar M; Subramanian T
Brain Res Brain Res Rev; 2005 Dec; 50(1):156-68. PubMed ID: 16026845
[TBL] [Abstract][Full Text] [Related]
2. Opioids and motor complications in Parkinson's disease.
Samadi P; Bédard PJ; Rouillard C
Trends Pharmacol Sci; 2006 Oct; 27(10):512-7. PubMed ID: 16908075
[TBL] [Abstract][Full Text] [Related]
3. L-DOPA-induced dyskinesia: cellular mechanisms and approaches to treatment.
Cenci MA
Parkinsonism Relat Disord; 2007; 13 Suppl 3():S263-7. PubMed ID: 18267248
[TBL] [Abstract][Full Text] [Related]
4. [Understanding and treating levodopa-induced dyskinesias].
Hadj Tahar A; Bédard PJ
Tunis Med; 1998 Dec; 76(12):437-47. PubMed ID: 10093483
[No Abstract] [Full Text] [Related]
5. Levodopa-induced dyskinesias in Parkinson's disease: etiology, impact on quality of life, and treatments.
Encarnacion EV; Hauser RA
Eur Neurol; 2008; 60(2):57-66. PubMed ID: 18480609
[TBL] [Abstract][Full Text] [Related]
6. Targeting metabotropic glutamate receptors as a new strategy against levodopa-induced dyskinesia in Parkinson's disease?
Picconi B; Calabresi P
Mov Disord; 2014 May; 29(6):715-9. PubMed ID: 24591264
[TBL] [Abstract][Full Text] [Related]
7. Role of receptor heterodimers in the development of L-dopa-induced dyskinesias in the 6-hydroxydopamine rat model of Parkinson's disease.
Fiorentini C; Busi C; Spano P; Missale C
Parkinsonism Relat Disord; 2008; 14 Suppl 2():S159-64. PubMed ID: 18638717
[TBL] [Abstract][Full Text] [Related]
8. Parkinson's disease--Part 2: Treatment of motor symptoms.
Weintraub D; Comella CL; Horn S
Am J Manag Care; 2008 Mar; 14(2 Suppl):S49-58. PubMed ID: 18402508
[TBL] [Abstract][Full Text] [Related]
9. Mechanisms of motor complications in treatment of Parkinson's disease.
Kumar A; Huang Z; de la Fuente-Fernández R
Adv Neurol; 2003; 91():193-201. PubMed ID: 12442678
[No Abstract] [Full Text] [Related]
10. Levodopa in the treatment of Parkinson's disease: current controversies.
Gerlach M; Reichmann H; Riederer P
Mov Disord; 2005 May; 20(5):643; author reply 643-4. PubMed ID: 15732130
[No Abstract] [Full Text] [Related]
11. l-DOPA dosage is critically involved in dyskinesia via loss of synaptic depotentiation.
Picconi B; Paillé V; Ghiglieri V; Bagetta V; Barone I; Lindgren HS; Bernardi G; Angela Cenci M; Calabresi P
Neurobiol Dis; 2008 Feb; 29(2):327-35. PubMed ID: 17997101
[TBL] [Abstract][Full Text] [Related]
12. Risk factors in development of motor complications in Chinese patients with idiopathic Parkinson's disease.
Kum WF; Gao J; Durairajan SS; Man SC; Xie LX; Lu JH; Fong WL; Li M
J Clin Neurosci; 2009 Aug; 16(8):1034-7. PubMed ID: 19428256
[TBL] [Abstract][Full Text] [Related]
13. New ideas on the origin of L-dopa-induced dyskinesias: age, genes and neural plasticity.
Linazasoro G
Trends Pharmacol Sci; 2005 Aug; 26(8):391-7. PubMed ID: 16009432
[TBL] [Abstract][Full Text] [Related]
14. Levodopa in the early treatment of Parkinson's disease.
Murata M
Parkinsonism Relat Disord; 2009 Jan; 15 Suppl 1():S17-20. PubMed ID: 19131036
[TBL] [Abstract][Full Text] [Related]
15. Repetitive transcranial magnetic stimulation for levodopa-induced dyskinesias in Parkinson's disease.
Filipović SR; Rothwell JC; van de Warrenburg BP; Bhatia K
Mov Disord; 2009 Jan; 24(2):246-53. PubMed ID: 18951540
[TBL] [Abstract][Full Text] [Related]
16. Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia.
Muñoz A; Li Q; Gardoni F; Marcello E; Qin C; Carlsson T; Kirik D; Di Luca M; Björklund A; Bezard E; Carta M
Brain; 2008 Dec; 131(Pt 12):3380-94. PubMed ID: 18952677
[TBL] [Abstract][Full Text] [Related]
17. Slow oscillatory activity and levodopa-induced dyskinesias in Parkinson's disease.
Alonso-Frech F; Zamarbide I; Alegre M; Rodríguez-Oroz MC; Guridi J; Manrique M; Valencia M; Artieda J; Obeso JA
Brain; 2006 Jul; 129(Pt 7):1748-57. PubMed ID: 16684788
[TBL] [Abstract][Full Text] [Related]
18. [Physiopathology of parkinsonism and dyskinesias: lessons from surgical observations]].
Linazasoro G
Neurologia; 2001 Jan; 16(1):17-29. PubMed ID: 11234658
[TBL] [Abstract][Full Text] [Related]
19. Molecular mechanisms of L-DOPA-induced dyskinesia.
Jenner P
Nat Rev Neurosci; 2008 Sep; 9(9):665-77. PubMed ID: 18714325
[TBL] [Abstract][Full Text] [Related]
20. [Current developments in the long-term therapy of Parkinson syndrome].
Ludin HP
Schweiz Rundsch Med Prax; 1992 Nov; 81(48):1458-60. PubMed ID: 1448642
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
